Affiliate disclosure: Some links in this article are affiliate links. We may earn a commission at no additional cost to you.

Medical disclaimer: This article reviews published research on resveratrol and is informational only. It is not medical advice. Not medical advice. Consult a qualified healthcare professional before starting any supplement, particularly if you take medications, have a hormone-sensitive condition, or are on anticoagulant therapy.

What the label “Japanese knotweed extract” actually means

Pick up a trans-resveratrol supplement from Amazon, Life Extension, or NOW Foods and there is a good chance the Supplement Facts panel credits the source as Japanese knotweed root extract — or its botanical name, Polygonum cuspidatum, also classified as Reynoutria japonica. The label rarely explains why a plant most Britons know as an invasive garden problem ended up as the primary commercial source for a polyphenol most commonly associated with red wine.

The straightforward reason: the root of Polygonum cuspidatum — called 虎杖 (itadori) in Japan, where it has traditional Kampo medicine uses — concentrates trans-resveratrol at substantially higher levels than grape skin or other common botanical sources. The root extract can yield 50% or more trans-resveratrol by weight under standardized extraction. Grape skin, by comparison, contains resveratrol in quantities that require large volumes of material to process to supplement-grade concentrations. Commercial resveratrol production shifted to Japanese knotweed root as the more practical agricultural source, with most global supply now originating from growers in China’s Sichuan and Hunan provinces who cultivate the plant specifically for this purpose.

The Japanese connection is therefore real in botanical origin — 虎杖 is a native Japanese and East Asian plant with documented Kampo uses — but the supplement supply chain today runs primarily through Chinese agricultural production rather than Japanese manufacturing. That does not affect the compound’s chemistry, but buyers who infer a supply-chain quality premium from the Japanese plant name are conflating the origin of the species with the origin of the finished ingredient.

The SIRT1 calorie restriction hypothesis: where it came from and what the evidence debate became

The scientific case for resveratrol as a longevity-relevant compound has a clear origin point. A 2003 paper in Nature by Howitz et al. reported that resveratrol activated Sir2 — the yeast equivalent of mammalian SIRT1 — and appeared to extend lifespan in Saccharomyces cerevisiae by up to 70%. SIRT1 is a sirtuin enzyme involved in gene regulation, stress response, and metabolic adaptation. In calorie-restricted animals, SIRT1 activity is elevated, and the calorie restriction-lifespan connection in model organisms was well-established at that point. The hypothesis that resveratrol might mimic calorie restriction pharmacologically, without requiring food restriction, generated substantial scientific and popular attention.

A 2006 paper in Nature from Baur et al. extended the story to mice: high-dose resveratrol supplementation was associated with metabolic improvements in obese mice on a high-fat diet, with the resveratrol group showing insulin sensitivity and mitochondrial function markers that resembled lean controls, along with an apparent lifespan extension relative to high-fat-diet controls not given resveratrol. These findings contributed to a wave of commercial and academic interest that transformed resveratrol from a wine-chemistry curiosity to one of the most-discussed compounds in longevity research during that period.

What followed was a more complicated chapter. In 2010, researchers at Pfizer’s laboratories reported significant difficulty with the mechanism: the fluorescent probe used in the original SIRT1 binding assay appeared to produce an artifact that made resveratrol look like a stronger direct activator of SIRT1 than subsequent experiments without the probe could confirm. The subsequent debate about whether resveratrol activates SIRT1 directly, indirectly through AMPK phosphorylation, or through some combination involving the AMPK/PGC-1α pathway has not fully resolved as of 2026. The calorie restriction mimicry hypothesis remains scientifically active, but the mechanistic picture is substantially more uncertain than early popular coverage suggested.

What human trials have and have not shown

The human trial record for resveratrol is more extensive than for most compounds in the longevity supplement space, but the pattern of findings is specific and often mischaracterized in supplement marketing.

A frequently cited 2011 study in Cell Metabolism by Timmers et al. enrolled 11 obese but otherwise healthy middle-aged men in a 30-day randomized crossover trial of resveratrol (150 mg/day) versus placebo. The resveratrol arm showed improvements in insulin sensitivity markers, reduced triglycerides, and changes in skeletal muscle mitochondrial function associated with a metabolic shift that the authors described as consistent with calorie restriction. The results were directionally consistent with the preclinical hypothesis and statistically significant for several endpoints in that population. The fundamental limit: 11 people is not a sample size that establishes a generalizable clinical effect.

A separate 2011 trial in British Journal of Nutrition by Brasnyó et al. enrolled 19 subjects with type 2 diabetes in a randomized, double-blind crossover design. Resveratrol at 10 mg twice daily was associated with improvements in fasting glucose, insulin sensitivity index, and LDL oxidation markers compared to placebo. Again — a small sample, a metabolically compromised population, and biomarker endpoints rather than hard clinical outcomes.

The consistent pattern across published resveratrol RCTs is improvements in metabolic biomarkers — insulin sensitivity, inflammatory markers, lipid profiles — in populations with existing metabolic disease or cardiovascular risk factors, at doses ranging from 10 to 500 mg/day, in trials rarely exceeding three months. What the trial record does not contain, as of this article’s writing in 2026, is any adequately powered randomized trial demonstrating that resveratrol supplementation is associated with reduced cardiovascular events, extended human lifespan, or reduced all-cause mortality. The gap between biomarker signal and hard outcome in human data remains substantial.

Bioavailability adds a further complication. Resveratrol is rapidly metabolized in the liver after oral ingestion, with the compound largely converted to glucuronide and sulfate conjugates before entering systemic circulation at meaningful concentrations. Trials using formulations that include piperine (from black pepper extract) or micronized particles report higher plasma resveratrol levels, which may partially account for dose-response inconsistencies across the literature. When comparing products, formulation — not just the stated milligram dose — affects how much of the active compound actually reaches circulation.

Side effects and interactions

Short-term resveratrol supplementation at doses studied in published trials — typically 100–500 mg/day — has a generally clean tolerability profile relative to placebo. Gastrointestinal effects, including nausea, loose stool, and abdominal discomfort, are the most commonly reported adverse events. These appear dose-dependent and are rarely described as severe in trials at standard supplementation ranges.

Interactions that warrant clinician disclosure before starting:

• Anticoagulants (warfarin, apixaban): Resveratrol has demonstrated antiplatelet activity in laboratory models and has the potential to inhibit CYP2C9, an enzyme involved in warfarin metabolism. The combined effect could alter anticoagulation status in clinically unpredictable ways. Anyone on anticoagulant therapy should not supplement resveratrol without first discussing this with their prescribing clinician.
• Hormone-sensitive conditions: Resveratrol has shown weak estrogen-like (phytoestrogenic) activity in some experimental contexts. Clinical significance in humans is not well characterized, but caution is appropriate for anyone with a personal history of hormone-sensitive cancer or who takes hormone-modulating medications.
• Other CYP2C9 substrates: Medications metabolized through CYP2C9 — including certain NSAIDs, some diabetes medications, and other blood thinners — may be affected. A review of your current medication list with a pharmacist or clinician is a sensible first step.
• Active cancer treatment: Resveratrol’s interaction with oncologic treatment involves mechanisms that are not yet well characterized in the clinical literature. This is a question for an oncologist, not a supplement label.

Long-term controlled safety data beyond 12 months in human trials is limited for this compound. The absence of reported problems in shorter trials is not a substitute for that data.

How to source trans-resveratrol supplements

For buyers in the US, several established supplement manufacturers offer trans-resveratrol capsules on Amazon:

• Jarrow Formulas Resveratrol — a widely distributed option standardized to trans-resveratrol content at consistent dosing. Available on Amazon.
• Life Extension Optimized Resveratrol — Life Extension publishes third-party testing documentation and formulates with additional polyphenol compounds. Available on Amazon.
• NOW Foods Natural Resveratrol — a lower-cost option from an established manufacturer with a transparent ingredient history. Available on Amazon.

When comparing products:

• Check that the label specifies trans-resveratrol, not just “resveratrol.” Trans-resveratrol is the biologically active isomer; cis-resveratrol is less studied and generally present in smaller amounts in standardized extracts.
• Look for standardized Japanese knotweed root extract with a stated percentage of trans-resveratrol, so the milligram content of the active compound is clear rather than implied.
• Piperine (BioPerine) co-formulations aim to improve absorption. Whether this matters meaningfully for the outcomes you care about is uncertain in the human data, but it reflects formulation investment that some buyers find worth the price difference.

iHerb carries resveratrol options from established supplement brands that ship internationally for buyers outside the US.

Who should hold off, and what to discuss with a clinician

Populations for whom a clinician conversation should come before any resveratrol supplement decision:

• Anyone on warfarin, apixaban, or other anticoagulant medications
• Anyone with a personal history of hormone-sensitive cancer (breast, uterine, ovarian)
• Anyone taking medications primarily metabolized through CYP2C9
• Anyone undergoing active cancer treatment
• Pregnant or breastfeeding individuals (no controlled safety data exists in these populations)

The calibrated summary of the resveratrol evidence in 2026: the mechanistic hypothesis linking resveratrol to SIRT1 activation and calorie-restriction mimicry is scientifically active but substantially more contested than early coverage suggested. The human trial data shows consistent metabolic biomarker signals in people with existing metabolic conditions at doses of 100–500 mg/day. The distance between those biomarker findings and hard clinical outcomes — cardiovascular events, mortality, any confirmed longevity effect — has not been closed by controlled human trial evidence. For the broader polyphenol picture, the dietary evidence for plant-rich Japanese dietary patterns is better established than the supplement-dose resveratrol evidence, and that difference is worth carrying into any decision about supplementation.

---

See also: Spermidine and Autophagy: Natto Research and Dietary Polyamine Data, CoQ10 After 40: Japan’s Kaneka QH Ubiquinol Research, iHerb Japanese Supplement Guide.